The 8th international research symposium on the Marfan Syndrome and related conditions (Q57150264)

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys-Dietz syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Surgical management of aortic root disease in Marfan syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

A technique for complete replacement of the ascending aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

The new Ghent criteria for Marfan syndrome: what do they change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

S100A12 mediates aortic wall remodeling and aortic aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Fibulin-4 deficiency results in ascending aortic aneurysms: a potential link between abnormal smooth muscle cell phenotype and aneurysm progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Medical management of Marfan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Recurrent chromosome 16p13.1 duplications are a risk factor for aortic dissections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Lessons on the pathogenesis of aneurysm from heritable conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

The revised Ghent nosology for the Marfan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Aneurysm syndromes caused by mutations in the TGF-beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Two-dimensional echocardiographic aortic root dimensions in normal children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Missense mutations of conserved glycine residues in fibrillin-1 highlight a potential subtype of cb-EGF-like domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386

Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: Analysis of early outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.A.34386